Clinical Validation of an Ultra High-Throughput Spiral Microfluidics for the Detection and Enrichment of Viable Circulating Tumor Cells
Name
Khoo-2014-Clinical Validation.pdf
Size
1.04 MB
Format
Adobe PDF
Checksum (MD5)
f33fdd778cced26e0f24c570305124fc
Author(s)
Khoo, Bee Luan
Warkiani, Majid Ebrahimi
Tan, Daniel Shao-Weng
Bhagat, Ali Asgar S.
Irwin, Darryl
Lau, Dawn Pingxi
Lim, Alvin S. T.
Lim, Kiat Hon
Krisna, Sai Sakktee
Lim, Wan-Teck
Date Issued
July 2014
Journal
PLoS ONE
Publisher
Public Library of Science
Citation
Khoo, Bee Luan, Majid Ebrahimi Warkiani, Daniel Shao-Weng Tan, Ali Asgar S. Bhagat, Darryl Irwin, Dawn Pingxi Lau, Alvin S. T. Lim, et al. “Clinical Validation of an Ultra High-Throughput Spiral Microfluidics for the Detection and Enrichment of Viable Circulating Tumor Cells.” Edited by Hong Wanjin. PLoS ONE 9, no. 7 (July 7, 2014): e99409.
Version
Final published version
Abstract
Background:
Circulating tumor cells (CTCs) are cancer cells that can be isolated via liquid biopsy from blood and can be phenotypically and genetically characterized to provide critical information for guiding cancer treatment. Current analysis of CTCs is hindered by the throughput, selectivity and specificity of devices or assays used in CTC detection and isolation.
Methodology/Principal Findings:
Here, we enriched and characterized putative CTCs from blood samples of patients with both advanced stage metastatic breast and lung cancers using a novel multiplexed spiral microfluidic chip. This system detected putative CTCs under high sensitivity (100%, n = 56) (Breast cancer samples: 12–1275 CTCs/ml; Lung cancer samples: 10–1535 CTCs/ml) rapidly from clinically relevant blood volumes (7.5 ml under 5 min). Blood samples were completely separated into plasma, CTCs and PBMCs components and each fraction were characterized with immunophenotyping (Pan-cytokeratin/CD45, CD44/CD24, EpCAM), fluorescence in-situ hybridization (FISH) (EML4-ALK) or targeted somatic mutation analysis. We used an ultra-sensitive mass spectrometry based system to highlight the presence of an EGFR-activating mutation in both isolated CTCs and plasma cell-free DNA (cf-DNA), and demonstrate concordance with the original tumor-biopsy samples.
Conclusions/Significance:
We have clinically validated our multiplexed microfluidic chip for the ultra high-throughput, low-cost and label-free enrichment of CTCs. Retrieved cells were unlabeled and viable, enabling potential propagation and real-time downstream analysis using next generation sequencing (NGS) or proteomic analysis.
MIT Department
Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1371/journal.pone.0099409
